[Risk factors for duration of urinary incontinence after radical prostatectomy].
OBJECTIVE
In this study, we examined risk factors for duration of incontinence after radical prostatectomy at our hospital.


METHODS
From April 1988 to March 2000, 45 patients with prostate cancer underwent retropubic radical prostatectomy at our hospital. Thirty-eight of 45 patients could be followed up. The patients' age, height, weight, body mass index (BMI), preoperative prostatic specific antigen level, clinical stage, nerve-sparing surgery or none, operation time, bleeding volume, resected prostate weight, cancer positive or negative at surgical margins, postoperative stage, radiation therapy or none, anti-androgen therapy or none, duration of postoperative incontinence, and follow-up period were examined.


RESULTS
All patients had postoperative stress incontinence, and no one had urge incontinence. Medians of duration of postoperative incontinence and follow-up period were 5.5 and 12 months, respectively. When the patients were divided into 2 groups by the value of each parameter, postoperative anti-androgen therapy (chi 2 test, p = 0.0429) and high BMI (> or = 25.0 kg/m2, p = 0.0206) were related to the long duration (> or = 5.5 months) of postoperative incontinence.


CONCLUSIONS
These results suggest that common factors are involved in the etiology of prolonged incontinence after radical prostatectomy and genuine stress incontinence in women. Therefore, both body weight control and pelvic floor muscle exercise might be also important for the treatment of incontinence after radical prostatectomy.
Sugaya
Kimio
K
Department of Urology, Faculty of Medicine, University of the Ryukyus.
Oda
Masami
M
Nishijima
Saori
S
Shimabukuro
Shuichi
S
Ashimine
Satoshi
S
Sunabe
Tsuyoshi
T
Shimabukuro
Hiroichi
H
Goya
Masato
M
Kagawa
Haruo
H
Yonoh
Hiroyuki
H
Shiroma
Kazuo
K
Miyazato
Tomonori
T
Koyama
Yuzo
Y
Hatano
Tadashi
T
Ogawa
Yoshihide
Y
Owan
Tomoko
T
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D015992:Body Mass Index; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery; D012307:Risk Factors; D014550:Urinary Incontinence, Stress / Q000209:etiology*
D000726:Androgen Antagonists